Table 1.
Demographic, clinical, and pathologic characteristics of included patients (n = 1778)
| Variables | |
| Mean age at surgery ± SD (y) | 61.5 ± 6.5 |
| Median y of surgery | 2002 |
| Race | |
| White | 904 (51%) |
| African American | 751 (42%) |
| Other | 123 (7%) |
| BMI | |
| <25 kg/m2 | 395 (24%) |
| 25–29.9 kg/m2 | 765 (47%) |
| ≥30 kg/m2 | 478 (29%) |
| PSA (ng/mL) | |
| Mean ± SD | 9.2 ± 9.2 |
| Median (IQR) | 6.8 (4.9–10.3) |
| Biopsy Gleason Sum | |
| 2–6 | 1069 (61%) |
| 7 | 376 (21%) |
| 8–10 | 310 (18%) |
| Pathological Gleason Sum | |
| 2–6 | 713 (40%) |
| 7 | 686 (39%) |
| 8–10 | 379 (21%) |
| Percentage positive cores | |
| Mean ± SD | 35.3 ± 22.9 |
| Median (IQR) | 33.3 (16.7–50.0) |
| Prostate weight (grams) | |
| Mean ± SD | 44.2 ± 21.8 |
| Median (IQR) | 40.0 (31.0–50.7) |
| Extraprostatic extension | 378 (21%) |
| Positive surgical margins | 806 (45%) |
| Seminal vesicle invasion | 171 (10%) |
| Clinical stage | |
| T1a | 21 (1%) |
| T1b | 11 (1%) |
| T1c | 949 (58%) |
| T2X | 66 (4%) |
| T2a | 431 (26%) |
| T2b | 107 (7%) |
| T2c | 57 (3%) |
| T3 | 1 (0.1%) |
| Pathologic stage grouping | |
| Organ-confined, margin negative | 835 (47%) |
| EPE and/or positive margins | 761 (43%) |
| Seminal vesicle invasion | 157 (8%) |
| Lymph node involvement | 25 (1%) |
BMI, body mass index; EPE, extraprostatic extension; IQR, interquartile range; PSA, prostate-specific antigen.